Blood cancers like multiple myeloma (MM), lymphoma and leukaemia present complex treatment challenges due to their diverse molecular and phenotypic characteristics. Many of these cancers are diagnosed at advanced stages and relapse is common, underscoring the need for a fundamentally reimagined approach to elevate the standards of care.